SAB BIO Q3 2026 Earnings Call - SAB BIOTHERAPEUTICS INC

Explicit Guidance:

• Reaffirmed completion of Safeguard enrollment in Q4 2026.
• Expected top-line data for the Safeguard study in the second half of 2027.
• PRISE study expects to dose the first patient in the current quarter (Q4 2026).
• Projected cash runway: Existing cash balance ($205M as of Sept 30, 2026) sufficient to fund operations through 2028.
• Burn rate: PRISE expenses are already accounted for in the budgeted burn rate; no change to guidance required.
• Backlog/Pipeline: Enrollment status for adult/adolescent Safeguard cohorts closed; pediatric enrollment in progress.

Business-Segment Outlook:

• SAB142 (Safeguard Study): Primary endpoint is C-peptide preservation (AUC); secondary endpoints include glycemic control (HbA1c, CGM) and long-term safety/immunogenicity (redosing capability).
• SAB142 (PRISE Study): Designed to potentially expand label to patients up to two years from Stage 3 T1D diagnosis; currently enrolling in US, Europe, and UK (7 sites).
• Cohort Expansion: PRISE includes cohorts for patients 100 days to 1 year post-diagnosis (Cohort 2) and 1 to 2 years post-diagnosis (Cohort 3) to validate beta-cell preservation at later disease stages.
• Label Strategy: Potential future label expansion driven by beta-cell availability rather than strict time-to-diagnosis, aiming to increase Total Addressable Market (TAM) and market penetration.
• Differentiation: Focus on long-term disease modification via redosing (enabled by fully human antibody structure) to preserve C-peptide over a lifetime, contrasting with single/dual-course competitors.
• Pediatric Enrollment: DMC approved step-down to children ages 5–11 in September; enrollment expected to accelerate.

Market and Competitive Outlook:

• Competitive Landscape: T-Field's new Stage 3 indication viewed as positive for the field, establishing a prescription pattern for pancreas preservation; SAB142 positioned as superior due to fewer dosing days and redosing capability.
• Physician/Patient Demand: Significant pent-up demand and high physician interest in the PRISE study, particularly for patients excluded by current T-Field time restrictions (e.g., >100 days post-diagnosis).
• Treatment Paradigm: Market shift anticipated toward preserving residual beta cells at diagnosis; SAB142 aims to redefine Stage 3 diagnosis management.
• Supply/Capacity: No specific capacity additions mentioned; reliance on proprietary TC bovine platform for antibody generation.

Macro / Industry Outlook:

• Regulatory Environment: FDA Fast-Track designation granted for new-onset Stage 3 T1D (Oct 2026); expected to facilitate frequent interactions, BLA rolling review, and potential priority review.
• Clinical Standards: Reliance on C-peptide preservation as a clinically validated surrogate for full approval in disease-modifying therapies.
• Investor Sentiment: Management notes "strong momentum" and "exemplary" clinical team performance as positive industry indicators.

Strategic Initiatives:

• Clinical Progression: Advancing SAB142 through Registrational Phase 2b (Safeguard) and Phase 3 (PRISE) to achieve top-line data in H2 2027.
• Infrastructure: Building commercial readiness and infrastructure to support long-term distribution of SAB142.
• Collaborations: Continuing investigator-led PRISE study supported by Breakthrough T1D grant; principal investigators confirmed at University of Florida, UZ Leuven, and King's College London.
• Enrollment Strategy: Leveraging safety data from Safeguard to initiate pediatric enrollment in PRISE immediately.

Risks and Headwinds to Outlook:

• Regulatory Risk: Fast-Track designation does not guarantee approval; FDA standards for BLA remain unchanged.
• Clinical Uncertainty: Top-line data timing (H2 2027) and efficacy results (C-peptide/HbA1c) are not guaranteed; PRISE timing not yet guided due to investigator-led nature.
• Safety Signals: Monitoring required for long-term redosing immunogenicity (though current data shows consistent safety profile across age groups).
  External Factors: Potential variability in patient enrollment rates or data monitoring committee findings could delay timelines.

Management Tone on the Future:

• Confidence Level: High confidence; describes clinical team performance as "exemplary" and product safety as "very consistent."
• Strategic Focus: Clear focus on completing Safeguard enrollment in Q4 2026 and delivering H2 2027 data.
• Sentiment: "Excited" about moving toward top-line data and "grateful" for community engagement; believes SAB142 has "meaningful potential" to change T1D treatment.
• Comparative Outlook: Optimistic regarding the field-wide shift to early intervention (T-Field uptake) benefiting SAB142's value proposition.

Miscellaneous:

• Funding: Received $13.4M in gross proceeds from July 2025 warrant exercises in Q3 2026.
• Expense Structure: R&D expenses ($18.1M in Q3 2026) and G&A ($7.8M) include significant non-cash stock-based compensation ($3.9M and $3.6M respectively), driven by headcount expansion for clinical advancement.
• Historical Context: Prior Phase I "super-responder" data (120-day follow-up) represents the complete dataset for that specific study; no data collected beyond 120 days for that cohort.